Journals / Ege Klinikleri Tıp Dergisi / 2020 / Cilt: 58 - Sayı: 1

Current Pharmacological Approaches in SARS-CoV- 2/COVID-19

SARS-CoV-2/COVID-19 Tedavisinde Güncel Farmakolojik Yaklaşımlar

Pages
30–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, drugs used for COVID-19 until April 2020, under clinical investigation and under development will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:SARS-CoV-2, also known as COVID-19, which originated from Wuhan city of China and spread all over the world in a short time, has caused a chain of events since December 2019 that have been fragile on public health and economic parameters.
📊
Key Findings & Data:In many of the COVID-19 test positive cases, mild and home quarantine requiring symptoms such as dry cough, fever, weakness are observed.
💡
Conclusion & Impact:In this review, drugs used for COVID-19 until April 2020, under clinical investigation and under development will be discussed.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

SARS-CoV-2, also known as COVID-19, which originated from Wuhan city of China and spread all over the world in a short time, has caused a chain of events since December 2019 that have been fragile on public health and economic parameters. Despite being reported regularly by the centers, any clear data on hospital applications and hospitalizations cannot be observed on a global scale. In many of the COVID-19 test positive cases, mild and home quarantine requiring symptoms such as dry cough, fever, weakness are observed. However, some individuals experience fulminant syndromes identified with COVID-19 such as viral pneumonia, respiratory failure that requires oxygenation, and acute respiratory distress syndrome that requires mechanical ventilation. As of April 2020, there is no developed vaccine, and medications are limited. In this review, drugs used for COVID-19 until April 2020, under clinical investigation and under development will be discussed.

Özet

Çin’in Wuhan şehrinden köken alarak tüm dünyaya kısa zamanda yayılan SARS-CoV-2 ya da bilinen diğer adıyla COVID-19; Aralık 2019’dan bu yana halk sağlığı ve ekonomik parametreler üzerinde kırılgan durumda olan olaylar zincirine neden olmuştur. Merkezler tarafından düzenli raporlanmasına rağmen, hastane başvuruları ve yatışlar ile ilgili, global ölçekte halen net bir veri gözlemlenememektedir. COVID-19 testi pozitif gözlenen birçok vakada, kuru öksürük, ateş, halsizlik gibi hafif ve ev karantinası gerektirecek semptomlar gözlenmektedir. Bununla birlikte, bazı bireylerde viral pnömoni, oksijenizasyona ihtiyaç duyan solunum yetmezliği ve mekanik ventilasyon gerektiren akut solunum sıkıntısı sendromu gibi COVID-19 ile özdeşleştirilen fulminan sendromlar gözlenir. Nisan 2020 itibariyle geliştirilmiş bir aşı bulunmamakta, ilaç tedavileri de sınırlı kalmaktadır. Bu derlemede, COVID-19 için Nisan 2020 tarihine kadar kullanılan, klinik araştırması süren ve geliştirme aşamasında olan ilaçlardan bahsedilecektir.

🔖

Cite This Article

ÖNAL, B. (2020). Current Pharmacological Approaches in SARS-CoV- 2/COVID-19. Ege Klinikleri Tıp Dergisi, Cilt: 58 - Sayı: 1, 30–34. https://ajindex.com/articles/415786

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020
  2. 55(3):105924. 2.Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020:105948. 3.WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020 [Available from: https://www.who.int/dg/speeches/detail/who-director-general-sopening- remarks-at-the-media-briefing-on-covid-19---11-march-2020. 4.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. 5.Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020:105949. 6.Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020
  3. 55(3):105923. 7.Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020:105932. 8.Uddin M, Mustafa F, Rizvi TA, et al. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. 2020. 9.Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020
  4. 30(3):269-71. 10.Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment. https://ClinicalTrials.gov/show/NCT04292730. 11.Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS- 5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017
  5. 9(396). 12.de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERSCoV infection. Proc Natl Acad Sci U S A. 2020
  6. 117(12):6771-6. 13.Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020. 14.Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Eng